These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17718223)

  • 21. Points to consider: the roles of surveillance and epidemiology in advancing drug safety.
    Edwards R; Faich G; Tilson H;
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353
    [No Abstract]   [Full Text] [Related]  

  • 22. [A literature review of adverse drug reaction reports. Adverse drug effects can have genetical background].
    Rane A
    Lakartidningen; 2002 May; 99(20):2266-7. PubMed ID: 12082942
    [No Abstract]   [Full Text] [Related]  

  • 23. Improving pharmacovigilance in Europe.
    Moore N; Bégaud B
    BMJ; 2010 Apr; 340():c1694. PubMed ID: 20385717
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharmacoepidemiology].
    Hallas J; Sørensen HT
    Ugeskr Laeger; 2005 May; 167(20):2186-90. PubMed ID: 15987081
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug side-effects of the eye--a contribution to quality assurance in ophthalmology].
    Dangelmaier S; Weindler J; Ruprecht KW
    Klin Monbl Augenheilkd; 1996 May; 208(5):385-8. PubMed ID: 8766060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse drug reactions in developing countries.
    Rohra DK
    J Coll Physicians Surg Pak; 2004 May; 14(5):325. PubMed ID: 15225469
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparing 4 classification systems for drug-related problems: processes and functions.
    Björkman IK; Sanner MA; Bernsten CB
    Res Social Adm Pharm; 2008 Dec; 4(4):320-31. PubMed ID: 19064239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug-eruptions].
    Thielen AM; Toutous-Trellu L; Desmeules J
    Rev Med Suisse; 2008 Jul; 4(165):1671-5. PubMed ID: 18767294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusual and severe forms of adverse drug reactions.
    Gogtay N; Mangalvedhekar S; Kshirsagar NA
    J Assoc Physicians India; 1999 Aug; 47(8):847. PubMed ID: 10778648
    [No Abstract]   [Full Text] [Related]  

  • 31. Adverse drug reaction reporting--1998.
    Sutcliffe H
    CMAJ; 1999 Apr; 160(7):1051, 1055. PubMed ID: 10207351
    [No Abstract]   [Full Text] [Related]  

  • 32. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 33. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of adverse reactions to new medicines.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1996 Jun; 15(2):77-8. PubMed ID: 8836313
    [No Abstract]   [Full Text] [Related]  

  • 35. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel.
    Macedo AF; Marques FB; Ribeiro CF; Teixeira F
    Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):885-90. PubMed ID: 16059869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Welsh Adverse Drug Reactions Scheme: experience of a UK regional monitoring centre.
    Houghton JE; Pinto Pereira LM; Woods FJ; Richens A; Routledge PA
    Adverse Drug React Toxicol Rev; 1996 Jun; 15(2):93-107. PubMed ID: 8836315
    [No Abstract]   [Full Text] [Related]  

  • 37. The national registry of drug-induced ocular side effects.
    Fraunfelder FT; Meyer SM
    Aust J Ophthalmol; 1984 May; 12(2):129-31. PubMed ID: 6487182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rethinking the numbers on adverse drug reactions.
    Lexchin J
    CMAJ; 1999 May; 160(10):1432. PubMed ID: 10352628
    [No Abstract]   [Full Text] [Related]  

  • 39. Advances in the pharmacogenomics of adverse drug reactions.
    Alvarado I; Wong ML; Licinio J
    Pharmacogenomics J; 2002; 2(5):273. PubMed ID: 12439730
    [No Abstract]   [Full Text] [Related]  

  • 40. Monitoring for adverse drug events.
    Kennedy DL; Goldman SA
    Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.